Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Guzman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Public Health|October 3, 2019
Myers et al. RespondJulie E Myers, Davida Farhat, Adrian Guzman, et al.
American Journal of Public Health|May 9, 2019
Pharmacists in HIV Prevention: An Untapped PotentialJulie E Myers, Davida Farhat, Adrian Guzman, et al.
Lab on a Chip|September 12, 2025
Size-independent and automated single-colony-resolution microdroplet dispensingHaemin Jung, Han Zhang, Jacob Hooper, et al.
Analytica Chimica Acta|May 15, 2025
Rapid filamentous fungi gene knockout identification through high-throughput droplet microfluidicsYuwen Li, Jing Dai, Huan Zhang, et al.
Science Advances|July 20, 2022
FIDELITY: A quality control system for droplet microfluidicsHan Zhang, Can Huang, Yuwen Li, et al.
Microbiology Spectrum|February 27, 2023
Soil Properties Correlate with Microbial Community Structure in Qatari Arid SoilsSini Skariah, Sara Abdul-Majid, Anthony G Hay, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Public Health|October 3, 2019
Myers et al. RespondJulie E Myers, Davida Farhat, Adrian Guzman, et al.
American Journal of Public Health|May 9, 2019
Pharmacists in HIV Prevention: An Untapped PotentialJulie E Myers, Davida Farhat, Adrian Guzman, et al.
Lab on a Chip|September 12, 2025
Size-independent and automated single-colony-resolution microdroplet dispensingHaemin Jung, Han Zhang, Jacob Hooper, et al.
Analytica Chimica Acta|May 15, 2025
Rapid filamentous fungi gene knockout identification through high-throughput droplet microfluidicsYuwen Li, Jing Dai, Huan Zhang, et al.
Science Advances|July 20, 2022
FIDELITY: A quality control system for droplet microfluidicsHan Zhang, Can Huang, Yuwen Li, et al.
Microbiology Spectrum|February 27, 2023
Soil Properties Correlate with Microbial Community Structure in Qatari Arid SoilsSini Skariah, Sara Abdul-Majid, Anthony G Hay, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Ritu Salani, Mary McCormack, Yong-Man Kim, et al.
Pageof 1